Skip to main content
MANNKIND CORP logo

MANNKIND CORP — Investor Relations & Filings

Ticker · MNKD ISIN · US56400P7069 LEI · 213800GFBCNY1ZFST722 US Manufacturing
Open in API
Filings indexed 1,205 across all filing types
Latest filing 2015-11-09 Capital/Financing Update
Country US United States of America
Listing US MNKD

About MANNKIND CORP

https://mannkindcorp.com/

MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of therapeutic products and devices. The company specializes in inhaled therapies for patients with cardiometabolic and orphan lung diseases. Its portfolio includes Afrezza®, an inhaled insulin for diabetes, and Tyvaso DPI®, a dry powder inhaler for pulmonary hypertension developed in collaboration with United Therapeutics. Through its acquisition of scPharmaceuticals, MannKind also markets FUROSCIX®, a subcutaneous treatment for edema in adults with chronic heart failure. The company's pipeline is focused on expanding indications for its existing products, including a pediatric application for Afrezza.

Recent filings

Filing Released Lang Actions
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement and accompanying prospectus related to an offering of common stock. It includes detailed information about the securities being offered, registration fees, use of proceeds, risk factors, plan of distribution, and legal matters. The document references Rule 424(b)(5) and Form S-3 registration, which are typical for securities offerings. It is not a financial report, earnings release, management discussion, or any other type of report but rather a detailed offering document for capital raising. Therefore, it fits the definition of a Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full offering details, not just an announcement or a brief summary, confirming it is a full financing document rather than a report publication announcement or regulatory filing.
2015-11-09 English
FORM 8-K FILING DOCUMENT
Earnings Release Classification · 95% confidence The document is a Form 8-K filing with the SEC, dated November 9, 2015, reporting the financial results for the third quarter ended September 30, 2015. It specifically states that the press release announcing the financial results is attached as Exhibit 99.1. The document itself is a current report announcing the earnings release, not the full earnings report or detailed financial statements. The length is 3349 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, initial announcements of quarterly financial results are classified as Earnings Release (ER).
2015-11-09 English
FORM 10-Q
Interim / Quarterly Report Q3 2015
2015-11-09 English
FORM 3 SUBMISSION
Director's Dealing
2015-10-16 English
FORM 3 SUBMISSION
Director's Dealing
2015-10-16 English
FORM 3 SUBMISSION
Director's Dealing
2015-10-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.